{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:34:08Z","timestamp":1792089248154,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.molmed.2020.12.001","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T16:28:19Z","timestamp":1610209699000},"page":"436-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery"],"prefix":"10.1016","volume":"27","author":[{"given":"Hannah C.","family":"Zierden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Josyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2020.12.001_bb0005","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2014.04.033","article-title":"Nanoparticle-based drug delivery to the vagina: a review","volume":"190","author":"Ensign","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0015","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1538-7836.2005.01328.x","article-title":"Spatial and temporal dynamics of the endothelium","volume":"3","author":"Aird","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.molmed.2020.12.001_bb0020","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/IJG.0000000000000107","article-title":"The blood-aqueous barrier in health and disease","volume":"23","author":"Coca-Prados","year":"2014","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.molmed.2020.12.001_bb0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier","volume":"21","author":"Cunha-Vaz","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0030","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.09.023","article-title":"The biology of mucus: composition, synthesis and organization","volume":"124","author":"Bansil","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0050","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.12.001_bb0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1073\/pnas.0911748107","article-title":"Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses","volume":"107","author":"Lai","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.12.001_bb0060","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1016\/j.biomaterials.2013.05.039","article-title":"Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake","volume":"34","author":"Ensign","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2020.12.001_bb0065","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/adhm.201600599","article-title":"Mucus-penetrating nanosuspensions for enhanced delivery of poorly soluble drugs to mucosal surfaces","volume":"5","author":"Yu","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.molmed.2020.12.001_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biomaterials.2018.09.005","article-title":"Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease","volume":"185","author":"Date","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2020.12.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01644-17","article-title":"Hypo-osmolar formulation of tenofovir (TFV) enema promotes uptake and metabolism of TFV in tissues, leading to prevention of SHIV\/SIV infection","volume":"62","author":"Xiao","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2020.12.001_bb0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2018.12.046","article-title":"Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth","volume":"295","author":"Hoang","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.addr.2015.03.017","article-title":"Particle tracking in drug and gene delivery research: state-of-the-art applications and methods","volume":"91","author":"Schuster","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12551-012-0066-y","article-title":"The emergence of multiple particle tracking in intracellular trafficking of nanomedicines","volume":"4","author":"Kim","year":"2012","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2004.06.001","article-title":"Real-time multiple-particle tracking: applications to drug and gene delivery","volume":"57","author":"Suh","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003453","article-title":"Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus","volume":"4","author":"Ensign","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2020.12.001_bb0105","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.molmed.2020.12.001_bb0110","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0006-3495(01)75844-4","article-title":"Diffusion of macromolecules and virus-like particles in human cervical mucus","volume":"81","author":"Olmsted","year":"2001","journal-title":"Biophys. J."},{"key":"10.1016\/j.molmed.2020.12.001_bb0115","doi-asserted-by":"crossref","first-page":"1900088","DOI":"10.1183\/13993003.00088-2019","article-title":"Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD","volume":"54","author":"Chisholm","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.molmed.2020.12.001_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2017.07.015","article-title":"Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials","volume":"124","author":"Khutoryanskiy","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/nnm-2016-0047","article-title":"Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo","volume":"11","author":"Maisel","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.molmed.2020.12.001_bb0130","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/acs.nanolett.9b04841","article-title":"Enhanced transport of shape and rigidity-tuned alpha-lactalbumin nanotubes across intestinal mucus and cellular barriers","volume":"20","author":"Bao","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.molmed.2020.12.001_bb0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2020.12.001_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6245","article-title":"Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth","volume":"13","author":"Zierden","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2020.12.001_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/2211738507666190401142530","article-title":"The scalability of wet ball milling for the production of nanosuspensions","volume":"7","author":"Lestari","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0150","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jconrel.2013.08.006","article-title":"Stability of nanosuspensions in drug delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40824-020-0184-8","article-title":"Emerging role of nanosuspensions in drug delivery systems","volume":"24","author":"Jacob","year":"2020","journal-title":"Biomater. Res."},{"key":"10.1016\/j.molmed.2020.12.001_bb0160","series-title":"Nanoparticles in Pharmacotherapy","first-page":"23","article-title":"Nanostructures in Pharma: Elixir to Oral Medicine","author":"Bommana","year":"2019"},{"key":"10.1016\/j.molmed.2020.12.001_bb0165","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.2042-7158.2010.01022.x","article-title":"Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods","volume":"62","author":"Peltonen","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2018.09.014","article-title":"Impact of anti-PEG antibodies on PEGylated nanoparticles fate in vivo","volume":"287","author":"Park","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.actbio.2016.07.019","article-title":"Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus","volume":"43","author":"Henry","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.molmed.2020.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1163\/156856296X00543","article-title":"Mucoadhesive poly(vinyl alcohol) hydrogels produced by freezing\/thawing processes: applications in the development of wound healing systems","volume":"7","author":"Mongia","year":"1996","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.molmed.2020.12.001_bb0185","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.addr.2005.07.003","article-title":"The use of mucoadhesive polymers in buccal drug delivery","volume":"57","author":"Salamat-Miller","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2011.08.032","article-title":"A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles","volume":"157","author":"Mert","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2013.05.035","article-title":"Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus","volume":"170","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0200","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.nano.2016.04.006","article-title":"Mucus-penetrating nanoparticles made with \"mucoadhesive\" poly(vinyl alcohol)","volume":"12","author":"Popov","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.molmed.2020.12.001_bb0205","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1039\/C6BM00375C","article-title":"Side chain variations radically alter the diffusion of poly(2-alkyl-2-oxazoline) functionalised nanoparticles through a mucosal barrier","volume":"4","author":"Mansfield","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.molmed.2020.12.001_bb0210","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1039\/C6PY01113F","article-title":"Poly(d,l-lactic acid)-block-poly(N-(2-hydroxypropyl)methacrylamide) nanoparticles for overcoming accelerated blood clearance and achieving efficient anti-tumor therapy","volume":"7","author":"Du","year":"2016","journal-title":"Polym. Chem."},{"key":"10.1016\/j.molmed.2020.12.001_bb0215","doi-asserted-by":"crossref","first-page":"25444","DOI":"10.1021\/acsami.6b08183","article-title":"Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers","volume":"8","author":"Shan","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.molmed.2020.12.001_bb0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpb.2017.12.017","article-title":"Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: proof of concept, challenges and pitfalls","volume":"124","author":"Nafee","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2018.09.055","article-title":"Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model","volume":"553","author":"Leal","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2015.11.003","article-title":"Mucoadhesive vs. mucopenetrating particulate drug delivery","volume":"98","author":"Netsomboon","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0235","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejpb.2015.01.005","article-title":"Methods to determine the interactions of micro- and nanoparticles with mucus","volume":"96","author":"Griessinger","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0240","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejpb.2015.01.022","article-title":"Nano-carrier systems: strategies to overcome the mucus gel barrier","volume":"96","author":"Dunnhaupt","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2017.08.114","article-title":"Protease-functionalized mucus penetrating microparticles: in-vivo evidence for their potential","volume":"532","author":"Mahmood","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0250","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/mt.2011.160","article-title":"N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles","volume":"19","author":"Suk","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0255","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1073\/pnas.1722338115","article-title":"Ionic liquids for oral insulin delivery","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.12.001_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2018.01.014","article-title":"Technological strategies to overcome the mucus barrier in mucosal drug delivery","volume":"124","author":"das Neves","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0265","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.molmed.2020.12.001_bb0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0275","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2020.0022","article-title":"Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions","volume":"36","author":"Popov","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","article-title":"Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation","volume":"35","author":"Rodrigues","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.molmed.2020.12.001_bb0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1475-1313.2008.00577.x","article-title":"Spontaneous blinking in healthy persons: an optoelectronic study of eyelid motion","volume":"28","author":"Sforza","year":"2008","journal-title":"Ophthalmic Physiol. Opt."},{"key":"10.1016\/j.molmed.2020.12.001_bb0290","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/OPTH.S185800","article-title":"Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery","volume":"13","author":"Kim","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0295","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/jop.2013.0142","article-title":"Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%","volume":"30","author":"Glogowski","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","article-title":"Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation","volume":"3","author":"Schopf","year":"2014","journal-title":"Ophthalmol Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0305","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.molmed.2020.12.001_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0315","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.12.001_bb0320","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.12.001_bb0325","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0330","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","article-title":"Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections","volume":"119","author":"Hoang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.molmed.2020.12.001_bb0335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000213644","article-title":"Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab","volume":"223","author":"Karagiannis","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.molmed.2020.12.001_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1755-3768.2010.02064.x","article-title":"Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections","volume":"89","author":"Meyer","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0345","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/IAE.0b013e3181884fd2","article-title":"Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab","volume":"28","author":"Fintak","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.molmed.2020.12.001_bb0350","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13346-020-00733-4","article-title":"Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD)","volume":"10","author":"Yadav","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.molmed.2020.12.001_bb0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1997.tb48550.x","article-title":"The first uterine pass effect","volume":"828","author":"De Ziegler","year":"1997","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2020.12.001_bb0360","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.fertnstert.2010.02.033","article-title":"Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study","volume":"94","author":"Yanushpolsky","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.molmed.2020.12.001_bb0365","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ajog.2010.03.025","article-title":"Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle","volume":"202","author":"Kuon","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.molmed.2020.12.001_bb0370","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1080\/14767058.2018.1465555","article-title":"The association of different progesterone preparations with preterm birth prevention","volume":"32","author":"Krispin","year":"2018","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.molmed.2020.12.001_bb0375","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s11095-013-1287-x","article-title":"Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice","volume":"31","author":"das Neves","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.molmed.2020.12.001_bb0380","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp4002365","article-title":"In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine","volume":"10","author":"das Neves","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.12.029","article-title":"PEGylated liposomes for topical vaginal therapy improve delivery of interferon alpha","volume":"113","author":"Joraholmen","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0390","doi-asserted-by":"crossref","first-page":"111287","DOI":"10.1016\/j.colsurfb.2020.111287","article-title":"Mucus-penetrating PEGylated polysuccinimide-based nanocarrier for intravaginal delivery of siRNA battling sexually transmitted infections","volume":"196","author":"Currie","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.molmed.2020.12.001_bb0395","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.biomac.5b01480","article-title":"Pegylated polyaspartamide-polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus","volume":"17","author":"Craparo","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.molmed.2020.12.001_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008236","article-title":"The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis","volume":"16","author":"Hoang","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2020.12.001_bb0405","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","article-title":"Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS","volume":"62","author":"das Neves","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0410","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0415","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2018.06.029","article-title":"Surface modification with polyethylene glycol enhances colorectal distribution and retention of nanoparticles","volume":"130","author":"Nunes","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0420","doi-asserted-by":"crossref","first-page":"34942","DOI":"10.1021\/acsami.8b12214","article-title":"Noncovalent PEG coating of nanoparticle drug carriers improves the local pharmacokinetics of rectal anti-HIV microbicides","volume":"10","author":"Nunes","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.molmed.2020.12.001_bb0425","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/mt.2016.182","article-title":"The mucus barrier to inhaled gene therapy","volume":"24","author":"Duncan","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2020.12.001_bb0430","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2016.05.031","article-title":"Barriers to inhaled gene therapy of obstructive lung diseases: a review","volume":"240","author":"Kim","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0435","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0168-3659(03)00263-3","article-title":"Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs","volume":"91","author":"Surendrakumar","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0440","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0168-3659(02)00034-2","article-title":"Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation","volume":"80","author":"Sakagami","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2020.12.001_bb0450","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijpharm.2016.02.031","article-title":"Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles","volume":"502","author":"Popov","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0455","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.05.013","article-title":"Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis","volume":"527","author":"Torge","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0460","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2014.06.055","article-title":"Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors","volume":"192","author":"Nafee","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0465","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijpharm.2018.04.030","article-title":"Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases","volume":"545","author":"De Leo","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.12.001_bb0470","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.12.009","article-title":"Fate of PEGylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation","volume":"272","author":"Patil","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0475","doi-asserted-by":"crossref","first-page":"E6595","DOI":"10.1073\/pnas.1705407114","article-title":"Protein nanocages that penetrate airway mucus and tumor tissue","volume":"114","author":"Huang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.12.001_bb0480","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/acsnano.8b05399","article-title":"Hypoxia-tropic protein nanocages for modulation of tumor- and chemotherapy-associated hypoxia","volume":"13","author":"Huang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.molmed.2020.12.001_bb0485","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2020.12.001_bb0490","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2014.01.007","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"178","author":"Suk","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","article-title":"PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy","volume":"285","author":"Osman","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2020.12.001_bb0500","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.omtm.2018.03.006","article-title":"An adeno-associated viral vector capable of penetrating the mucus barrier to inhaled gene therapy","volume":"9","author":"Duncan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2020.12.001_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019919","article-title":"Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients","volume":"6","author":"Hida","year":"2011","journal-title":"PLoS One"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420303142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420303142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:21:52Z","timestamp":1761463312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491420303142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1471491420303142"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2020.12.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}